Exhibit 99.1

                         PDI Terminates Xylos Agreement

Upper Saddle River, NJ-- (January 20, 2004) PDI, Inc. (NASDAQ: PDII) announced
that it has given Xylos Corporation notice of its intent to terminate its sales,
marketing and distribution agreement with Xylos to promote Xylos' XCell(TM)
Wound Care Products. The termination will be effective as of May 16, 2004, which
is after the 135-day notice required by the agreement.

PDI reaffirms its 2004 guidance of $1.15 to $1.25 earnings per share.

About PDI

PDI, a premier healthcare sales and marketing company, provides strategic
alternatives to the portfolio challenges of biopharmaceutical and medical device
and diagnostics manufacturers. Focusing on two core businesses, sales and
marketing services and product commercialization, PDI leverages its expertise
and commercial infrastructure to maximize profitable brand growth. Manufacturers
choose the relationship which best meets their strategic and financial
objectives, ranging from individual or bundled service agreements to broader
commercial partnerships.

For more information, visit the Company's website at www.pdi-inc.com.

This press release contains forward-looking statements. Investors are cautioned
that these forward-looking statements are subject to numerous risks and
uncertainties, known and unknown, which could cause actual results and
developments to differ materially from those expressed or implied in such
statements. Please see the risk factors detailed from time to time in PDI's
periodic filings with the Securities and Exchange Commission, including without
limitation, PDI's Annual Report on Form 10-K for the year ended December 31,
2002, and PDI's periodic reports on Forms 10-Q and 8-K filed with the Securities
and Exchange Commission since January 1, 2003. The forward looking-statements in
this press release are based upon management's reasonable belief as of the date
hereof. PDI undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.